Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fully humanized antihuman HER2 monoclonal antibody

A fully human and antibody technology, applied in the direction of antibodies, anti-tumor drugs, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the problem that humanized antibodies are not very ideal therapeutic agents and injection intervals Short and other questions

Active Publication Date: 2012-06-13
广州誉嘉生物科技有限公司
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while the results obtained so far support that HER2 is a useful target for breast cancer immunotherapy, because there are still HAMA or HACA responses and the dose is as high as 440mg / dose, frequent injections are required due to short injection intervals, and the existing human-derived Antibodies are not yet ideal therapeutic agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fully humanized antihuman HER2 monoclonal antibody
  • Fully humanized antihuman HER2 monoclonal antibody
  • Fully humanized antihuman HER2 monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035] The invention provides an anti-human HER2 monoclonal antibody molecule. In particular, the present invention provides anti-human HER2 mAb molecules with high affinity and low off-rate. Preferably, the anti-human HER2 monoclonal antibody molecule of the present invention is composed of a light chain and / or a heavy chain with a fully human framework. For the convenience of description, the present invention is divided into the following aspects for description. I. anti-human HER2 monoclonal antibody molecules; II. preparation of anti-human HER2 monoclonal antibody molecules; III. formulations and methods of use for treatment; and IV. other uses of anti-human HER2 antibody molecules.

[0036] I. Anti-human HER2 antibody molecule

[0037] The monoclonal antibodies of the invention can be obtained using a variety of techniques including, but not limited to, the standard hybridoma technique published by Kohler and Milstein (1975, Nature 256:495). Although this technique is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fully humanized antihuman HER2 monoclonal antibody, particularly an antihuman HER2 monoclonal antibody having high affinity and low dissociation rate. The antihuman HER2 monoclonal antibody preferred by the invention comprises a fully humanized Fc region, a framework region, and a CDR region of a fully humanized light chain and / or heavy chain, wherein the CDR region is obtained by molecular evolution. The invention also discloses an application of a medicine composition consisting of the antihuman HER2 monoclonal antibody in treating human diseases and a method for using the antihuman HER2 monoclonal antibody in treatment.

Description

technical field [0001] The present invention relates to anti-human HER2 monoclonal antibody. The present invention is particularly concerned with high affinity low off-rate anti-human HER2 mAbs. The preferred anti-human HER2 monoclonal antibody of the present invention comprises a fully human Fc region and framework region, and a fully human light chain and / or heavy chain variable region obtained through molecular evolution. The invention also discloses the application of the pharmaceutical composition composed of the fully human antibody in the treatment of human diseases and the method of using the fully human antibody in the treatment. Background technique [0002] Human epidermal growth factor receptor 2 (HER2 for short), also known as HER2 / neu, ErbB-2, CD340 and p185, is a protein encoded by the homologous gene HER2 / neu of epidermal growth factor receptor, which can It leads to a significant increase in the invasiveness of breast cancer (Dank M. 2001, Orv Hetil. 18; 1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N1/19C12N1/21C12N5/10A61K39/395A61P35/00
CPCA61K39/395C07K2317/92C07K16/32C12N5/10C07K2317/732C07K2317/55C07K2317/73C07K16/30C07K2317/56A61P35/00
Inventor 刘庆法
Owner 广州誉嘉生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com